Interferon release does not add discriminatory value to smear-negative HIV-tuberculosis algorithms

European Respiratory Journal

Volumn 39, Issue 1, 2012, Pages 163-171

  Rangaka, M X ^a,c   Gideon, H P ^a   Wilkinson, K A ^a,d   Pai, M ^f   Mwansa Kambafwile, J ^a   Maartens, G ^a   Glynn, J R ^c   Boulle, A ^a   Fielding, K ^c   Goliath, R ^a   Titus, R ^a   Mathee, S ^b   Wilkinson, R J ^a,d,e  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Provincial Administration of the Western Cape   (South Africa)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

Diagnostic research; HIV; Incremental value; Interferon release assay; Mycobacterium tuberculosis; QuantiFERON1 TB gold in tube

Indexed keywords

INTERFERON;

ADULT; ALGORITHM; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE RELEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; FEMALE; GOLD STANDARD; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROBABILITY; QUANTIFERON TB GOLD TEST; RECEIVER OPERATING CHARACTERISTIC; SPUTUM SMEAR; TUBERCULIN TEST; TUBERCULOSIS;

ADULT; ALGORITHMS; AREA UNDER CURVE; FEMALE; HIV INFECTIONS; HUMANS; INFECTIOUS DISEASE MEDICINE; INTERFERON-GAMMA; INTERFERONS; ISONIAZID; MALE; MULTIVARIATE ANALYSIS; REPRODUCIBILITY OF RESULTS; SPUTUM; TREATMENT OUTCOME; TUBERCULIN TEST; TUBERCULOSIS;

EID: 84855400776     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00058911     Document Type: Article

References (50)

1. Maartens G, Wilkinson RJ. Tuberculosis. Lancet 2007; 370: 2030-2043. (Pubitemid 350236315)
2. World Health Organization. WHO Three I's Meeting. Intensified Case Finding (ICF), Isoniazid Preventive Therapy (IPT), and TB Infection Control (IC) with people living with HIV. Report of a joint World Health Organization HIV/AIDS and TB department meeting. Geneva, World health Organization, 2008.
3. Balcells ME, Thomas SL, Godfrey-Faussett P, et al. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis 2006; 12: 744-751. (Pubitemid 43726847)
4. Kranzer K, Houben RM, Glynn JR, et al. Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 93-102.
5. Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51: 823-829.
6. Meintjes G, Wilkinson RJ. Undiagnosed active tuberculosis in HIV-infected patients commencing antiretroviral therapy. Clin Infect Dis 2010; 51: 830-832.
7. Mosimaneotsile B, Talbot EA, Moeti TL, et al. Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana. Lancet 2003; 362: 1551-1552. (Pubitemid 37410196)
8. Mohammed A, Ehrlich R, Wood R, et al. Screening for tuberculosis in adults with advanced HIV infection prior to preventive therapy. Int J Tuberc Lung Dis 2004; 8: 792-795. (Pubitemid 38747158)
9. Day JH, Charalambous S, Fielding KL, et al. Screening for tuberculosis prior to isoniazid preventive therapy among HIV-infected gold miners in South Africa. Int J Tuberc Lung Dis 2006; 10: 523-529. (Pubitemid 43667640)
10. Cain KP, McCarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 2010; 362: 707-716.
11. Corbett EL, Bandason T, Cheung YB, et al. Prevalent infectious tuberculosis in Harare, Zimbabwe: burden, risk factors and implications for control. Int J Tuberc Lung Dis 2009; 13: 1231-1237.
12. Getahun H, Kittikraisak W, Heilig CM, et al. Development of a standardized screening rule of tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011; 8: e1000391.
13. Seshadri C, Uiso LO, Ostermann J, et al. Low sensitivity of T-cell based detection of tuberculosis among HIV co-infected Tanzanian in-patients. East Afr Med J 2008; 85: 442-449.
14. Nicol MP, Davies MA, Wood K, et al. Comparison of T-SPOT.TB assay and tuberculin skin test for the evaluation of young children at high risk for tuberculosis in a community setting. Paediatrics 2009; 123: 38-43.
15. Liao CH, Lai CC, Tan CK, et al. False-negative results by enzyme-linked immunospot assay for interferon-γ among patients with culture-confirmed tuberculosis. J Infect 2009; 59: 421-423.
16. Bamford AR, Crook AM, Clark JE, et al. Comparison of interferon-γ release assays and tuberculin skin test in predicting active tuberculosis (TB) in children in the UK: a paediatric TB network study. Arch Dis Child 2010; 95: 180-186.
17. Ling DI, Pai M, Davids V, et al. Are interferon-γ release assays useful for diagnosing active tuberculosis in a high-burden setting? Eur Respir J 2011; 38: 649-656.
18. World Health Organization. Strategic and Technical Advising Group for Tuberculosis (STAG-TB). Report of the Tenth Meeting. Geneva, World Health Organization, 2010.
19. Metcalfe JZ, Cattamanchi A, Vittinghoff E, et al. Evaluation of quantitative IFN-γ response for risk stratification of active tuberculosis suspects. Am J Respir Crit Care Med 2010; 181: 87-93.
20. Moons KG, Biesheuvel CJ, Grobbee DE. Test research versus diagnostic research. Clin Chem 2004; 50: 473-476. (Pubitemid 38297294)
21. Moons KG, Grobbee DE. Diagnostic studies as multivariable, prediction research. J Epidemiol Community Health 2002; 56: 337-338. (Pubitemid 34454555)
22. Moons KG, van ES GA, Michel BC, et al. Redundancy of single diagnostic test evaluation. Epidemiology 1999; 10: 276-281.
23. World Health Organization TB/HIV Working Group Stop TB Partnership. Priority research questions for TB/HIV in HIV-prevalent and resource-limited settings. Report No.: WHO/HTM/TB/2010. Geneva, World health Organization, 2010.
24. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36. (Pubitemid 12142173)
25. Corbett EL, Zezai A, Cheung YB, et al. Provider-initiated symptom screening for tuberculosis in Zimbabwe: diagnostic value and the effect of HIV status. Bull World Health Organ 2010; 88: 13-21.
26. Cattamanchi A, Smith R, Steingart KR, et al. Interferon-γ release assays for the diagnosis of latent tuberculosis infection in HIV-infected individuals: a systematic review and meta-analysis. J Acquir Immune Defic Syndr 2011; 56: 230-238.
27. Cattamanchi A, Ssewenyana I, Davis JL, et al. Role of interferon-γ release assays in the diagnosis of pulmonary tuberculosis in patients with advanced HIV infection. BMC Infect Dis 2010; 10: 75.
28. Davies MA, Connell T, Johannisen C, et al. Detection of tuberculosis in HIV-infected children using an enzyme-linked immunospot assay. AIDS 2009; 23: 961-969.
29. Mazurek M, Jereb J, Vernon A, et al. Updated guidelines for using interferon-γ release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010; 59: 1-25.
30. Greenland P, O'Malley PG.When is a newpredictionmarker useful? A consideration of lipoprotein-associated phospholipase A2 and C-reactive protein for stroke risk. Arch Intern Med 2005; 165: 2454-2456. (Pubitemid 41720004)
31. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003; 95: 634-635. (Pubitemid 36603708)
32. Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS 2005; 19: 2109-2116. (Pubitemid 41668999)
33. Lawn SD, Badri M, Wood R. Risk factors for tuberculosis among HIV-infected patients receiving antiretroviral treatment. Am J Respir Crit Care Med 2005; 172: 1348. (Pubitemid 43076575)
34. Lawn SD, Myer L, Bekker LG, et al. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20: 1605-1612. (Pubitemid 44162402)
35. Wilkinson KA, Seldon R, Meintjes G, et al. Dissection of regenerating T-cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Am J Respir Crit Care Med 2009; 180: 674-683.
36. Dosanjh DP, Hinks TS, Innes JA, et al. Improved diagnostic evaluation of suspected tuberculosis. Ann Intern Med 2008; 148: 325-336. (Pubitemid 351665463)
37. Chegou NN, Black GF, Kidd M, et al. Host markers in QuantiFERON supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulm Med 2009; 9: 21.
38. Barry CE 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7: 845-855.
39. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol 2009; 17: 183-188.
40. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973-977.
41. Rangaka MX, Wilkinson KA, Seldon R, et al. Effect of HIV-1 infection on T-cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2007; 175: 514-520. (Pubitemid 46354256)
42. Moons KG, van Es GA, Deckers JW, et al. Limitations of sensitivity, specificity, likelihood ratio, and Bayes' theorem in assessing diagnostic probabilities: a clinical example. Epidemiology 1997; 8: 12-17. (Pubitemid 27014215)
43. Cook NR. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin Chem 2008; 54: 17-23. (Pubitemid 351182592)
44. Greenland P. Comments on "Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond" by M.J. Pencina, R.B. D'Agostino Sr, R.B. D'Agostino Jr, R.S. Vasan, Statistics in Medicine (DOI: 10.1002/sim.2929). Stat Med 2008; 27: 188-190.
45. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 2010; 21: 128-138.
46. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172. (Pubitemid 351193639)
47. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; CD000171.
48. Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet 2011; 377: 1588-1598.
49. StopTB. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva, World Health Organization, 2011.
50. Peduzzi P, Concato J, Kemper E, et al. A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 1996; 49: 1373-1379. (Pubitemid 27028925)